Gareth Morgan

Immigrant scientist studying amyloidosis. Not a physician. He/him

[Gareth Morgan @wittyremarkhere]

With Professors Jeff Kelly and Joel Buxbaum at Scripps Research, I wrote about our goal of creating drugs to stabilize antibody light chains and suppress their misfolding and aggregation, as a potential therapy for AL amyloidosis (open access): https://t.co/aqgID5cx0u

[Gareth Morgan @wittyremarkhere]

Fantastic to see our competitive, market-driven healthcare system in action as BridgeBio launches a newly-approved TTR stabilizer molecule at a list price that's [checks notes] 10% higher than the indistinguishable competitor?

[Ahmad Masri @MasriAhmadMD]

DepleTTR-CM trial is now on https://t.co/5QFuhycc8b
Phase III trial of ALXN2220 (NI006) vs placebo
Fibril remover ( phase I results https://t.co/2D6HAYg5Np )
1000 patients, ATTR-CM, loop diuretics, NTproBNP > 2000.
PEP: ACM+CV events

https://t.co/RaxczA7rQ7
#CardioTwitter

[Vaishali Sanchorawala @vsanchorawala]

Mechanisms on pathophysiology of amyloid fibrillogenesis form @BU_Amyloidosis @wittyremarkhere
Kinetic evidence for multiple aggregation pathways in antibody light chain variable domains https://t.co/Ym7sHKndNm

[Gareth Morgan @wittyremarkhere]

@MarkMcConway1 @awechalekar Twitter is bad at context and detail. The paper says that there's not enough evidence to support the claim (by other authors in a recent study) that bortezomib is nephrotoxic, and that substantial earlier evidence points to it being safe. https://t.co/oxfTHbn1MT

[BU Amyloidosis Center @BU_Amyloidosis]

15 cases of AGelsolin amyloidosis: largest series in the US. 20% renal involvement, 7% cardiac involvement besides cranial, peripheral and autonomic neuropathy. @lis589 @vsanchorawala
https://t.co/rsdBiO37et

[Gareth Morgan @wittyremarkhere]

With apologies to Yiying Lu.

[Gareth Morgan @wittyremarkhere]

@pratt_ed I could have sworn we'd ordered 100mm tubes, but nope, they're 75mm, sorry

[Gareth Morgan @wittyremarkhere]

@pratt_ed We use these from Fisher for our FPLC: https://t.co/qv6VwUIOcy

[Scripps Research @scrippsresearch]

The Scripps Research community mourns the passing of Michael Oldstone, MD, esteemed virologist and professor emeritus, who helped establish the viral pathogenesis field and shaped our understanding of host immune responses https://t.co/v21IUqSVii

[Gareth Morgan @wittyremarkhere]

Kudos to @BridgeBioPharma for sticking with the trial after the "disappointing" (but not really surprising) 12-month data

[Gareth Morgan @wittyremarkhere]

Good to see that acoramidis met its endpoints for ATTR amyloidosis in the ATTribute-CM trial. Important that there's a significant benefit even in a cohort that was healthier than in previous ATTR trials.
https://t.co/JK0M5VHbSY

[Rich Giadone @rmgiadone]

Online now (@ISA_Amyloidosis)! S/o to @sabrina_ghosh for her hard work during the pandemic (this was her UNDERGRAD❗️thesis)! HUGE thanks to the 🐐 mentor @DrGJMurphy for letting me play junior PI (my first (and hopefully not last) senior author paper🥸)
https://t.co/ljBie1qyMO

[Gareth Morgan @wittyremarkhere]

@AaronGoodman33 No love for SLAMF7?

[Brett Sperry, MD @BrettSperryMD]

Big day for patients with ATTR amyloidosis, as the topline results of ATTRIBUTE-CM are positive!

Acoramidis showed significant benefit for the hierarchical composite of all-cause mortality, CV hospitalization, NTproBNP, and 6MW distance.

https://t.co/IKU5iJ5s3G

[Gareth Morgan @wittyremarkhere]

@vineetcardio @VincentRK Normal FLC + positive scintigraphy: likely ATTR
Abnormal FLC + negative scintigraphy: likely AL
Abnormal FLC + positive scintigraphy: could be either, MUST verify with typing
Normal FLC + negative scintigraphy: not amyloid, or a rarer variant like AApoA1
https://t.co/TVbpyGNH0G

[Amyloidosis Research Consortium @Amyloidosis_ARC]

The first generation of drug approvals in #ATTR #amyloidosis has reshaped the research landscape. This month's #AmyloidosisForum will consider how to effectively design trials against a backdrop of treatments that slow progression of the disease.
https://t.co/R7suiCWCGW

[Gareth Morgan @wittyremarkhere]

A review of our work to develop stabilizer drugs for AL amyloidosis is out today in Current Opinion in Chemical Biology: https://t.co/RRgdv6Tcn6
Highlights the work of @ScrippsGradPrgm alum Nick Yan, who developed high-efficacy molecules against a non-traditional drug target

[Vaishali Sanchorawala @vsanchorawala]

Congratulations to Dr Elena Klimtchuk of @BU_Amyloidosis in elucidating mechanism of amyloid fibrillogenesis.
Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 ligh… https://t.co/bVpw7Y5sj6

[Gareth Morgan @wittyremarkhere]

@sabrina_ghosh @Gates_Cambridge @UnivCamPharm Congratulations!

[Gareth Morgan @wittyremarkhere]

@darth attn @DrFNFurter